Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA7 | P43166 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16474350 | 0.90 | LMNA (0.50) | LMNACYP1A2CYP3A4MAOAHSD17B2 | |
| SCHEMBL14629680 | 0.87 | PTPN11 (0.43) | LMNACYP1A2CYP3A4MAOAHSD17B2 | |
| SCHEMBL2390084 | 0.85 | ALDH1A1 (0.46) | LMNAHSD17B2PTPN11CA12CA1 | |
| SCHEMBL1846303 | 0.84 | KDM4E (0.47) | LMNAHSD17B2NPC1CA12CA2 | |
| SCHEMBL3328123 | 0.83 | HTT (0.48) | HSD17B2NPC1CA12CA1CA2 | |
| SCHEMBL2049629 | 0.82 | RAB9A (0.42) | LMNAHSD17B2PTPN11NPC1CA12 | |
| SCHEMBL11122000 | 0.82 | TOP1 (0.47) | LMNANPC1SMN1; SMN2RAB9AHSD17B10 | |
| SCHEMBL11124197 | 0.81 | MAPT (0.49) | LMNANPC1ELANESMN1; SMN2RAB9A | |
| Acetic Acid SCHEMBL11123129 | 0.81 | LMNA (0.51) | LMNACYP1A2CYP3A4MAOAHSD17B2 | |
| SCHEMBL3330717 | 0.79 | BCL2L1 (0.45) | LMNACYP1A2CYP3A4MAOAHSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1244446-B1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2006-11-02 | — | — | EP | disclosed |
| US-6858630-B2 | Naphthimidazole derivatives and their use as thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-22 | — | — | US | disclosed |
| US-20030083361-A1 | Naphtho(1,2-d)imidazole derivatives; treating thrombocytopenia | SMITHKLINE BEECHAM CORPORATION | 2003-05-01 | — | — | US | disclosed |
| EP-1244446-A4 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-1244446-A1 | THROMBOPOIETIN MIMETICS | SmithKline Beecham Corporation (US) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001039773-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-06-07 | — | — | WO | disclosed |
| EP-0033831-B1 | SUBSTITUTED NAPHTHOIC ACIDS | AMERICAN CYANAMID COMPANY (US) | 1984-04-11 | — | — | EP | disclosed |
| WO-1982003550-A1 | SUBSTITUTED NAPHTHOIC ACIDS | AMERICAN CYANAMID CO (US) | 1982-10-28 | — | — | WO | disclosed |
| US-4291169-A | UREIDOS OF SUBSTITUTED NAPHTHOIC ACID AMINES CHEMICAL INTERMEDIATES | AMERICAN CYANAMID COMPANY (US) | 1981-09-22 | — | — | US | disclosed |
| EP-0033831-A2 | Substituted naphthoic acids | AMERICAN CYANAMID COMPANY (US) | 1981-08-19 | — | — | EP | disclosed |
| US-4275076-A | UREIDES OF SUBSTITUTED NAPHTHOIC ACIDS AS INHIBITORS OF CONNECTIVE TISSUE DESTRUCTION | AMERICAN CYANAMID COMPANY (US) | 1981-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083361-A1 | Naphtho(1,2-d)imidazole derivatives; treating thrombocytopenia | MPL, THPO, TPO | LMNA 3899/4885CYP1A2 2795/4885CYP3A4 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.